Stock Screener App

Gratuito -

Installare

8.66

5.87% -0.54

Immatics N V (IMTX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Forum Previsione

Immatics N V Borsa (IMTX) Ultime notizie

Immatics NV (IMTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Immatics NV (IMTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Immatics NV (IMTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Immatics Market Sentiment - Benzinga

Immatics NV (IMTX) Cash Flow - TradingKey

Immatics N.V. Revenue Breakdown – NASDAQ:IMTX - TradingView

IMTX|Immatics NV|Price:9.080|Chg%:-0.210 - TradingKey

Immatics NV (IMTX) Income Statement - TradingKey

Immatics N.V. (IMTX) Stock Analysis: A Deep Dive Into Its 103% Potential Upside - DirectorsTalk Interviews

Immatics NV (IMTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Immatics NV : Leerink Partners Assumes Covera - Moomoo

Immatics stock trades steady as pipeline and cash position frame biotech outlook - Ad-hoc-news.de

Immatics to present PRAME cell therapy anzu-cel Phase 1b melanoma data at ESMO 2026 - Bitget

Immatics N.V. (IMTX) Stock: Cancer Treatment Pipeline Gains Momentum With Cell Therapy and Bispecific Programs - parameter.io

Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 - Investing News Network

MRNA Advances Cancer Pipeline With New Immunotherapy Study - TradingView

Immatics Announces Three ESMO 2026 Presentations Highlighting PRAME Cell Therapy and Bispecific Pipeline - Quiver Quantitative

Immatics’ three ESMO presentations span melanoma and solid tumors - Stock Titan

Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Miss Reflects Clinical-Stage R&D InvestmentEarnings Growth Analysis - dars.gov.et

Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Miss Amid Continued Pipeline ProgressPre-Announcement Alert - dars.gov.et

Immatics (IMTX) Gains Momentum, Approaches Key Resistance LevelNew Highs New Lows - dars.gov.et

(IMTX) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Immatics (IMTX) Slides 3.11% Amid Biotech Sector Pressure – Support at $9.17 in FocusRounding Bottom - dars.gov.et

Immatics (IMTX) Holds Near Support as Slight Dip Signals Cautious TradingGap Down Bounce Plays - dars.gov.et

Immatics stock holds attention. The focus shifts to its pipeline. - Ad Hoc News

Immatics (IMTX) Q1 2026 Earnings: EPS Miss Weighs on Pre-Revenue Biotech StockRevenue Beat Analysis - Bölüm Sonu Canavarı

Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Misses Estimates as Development Costs WeighQuarterly Earnings - dars.gov.et

Immatics N.V. Q1 2026 Earnings: EPS Miss Reflects Clinical-Stage InvestmentEarnings Sentiment Score - dars.gov.et

Responsive Playbooks and the IMTX Inflection - Stock Traders Daily

Immatics N.V. Actuals & Estimates (NASDAQ:IMTX) - TradingView

Immatics (IMTX) Q1 2026 Earnings: Wider-Than-Expected Loss Reflects R&D InvestmentRevenue Guidance Range - dars.gov.et

Enterprise value to revenue forward of Immatics N.V. – NASDAQ:IMTX - TradingView

Price to book forward of Immatics N.V. – NASDAQ:IMTX - TradingView

Enterprise value to EBIT forward of Immatics N.V. – NASDAQ:IMTX - TradingView

Enterprise value to EBIT forward of Immatics N.V. – MUN:4A3 - TradingView

IMTX Forecast — Price Target — Prediction for 2027 - TradingView

Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Miss Reflects Higher R&D Investment; Pipeline Progress Continues - dars.gov.et

Immatics N.V. Actuals & Estimates (TRADEGATE:4A3) - TradingView

Immatics N.V. Actuals & Estimates (FWB:4A3) - TradingView

Immatics NV (IMTXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Immatics NV (IMTX) Institutional Confidence - TradingKey

Understanding the Setup: (IMTX) and Scalable Risk - Stock Traders Daily

Immatics Shareholders Approve All Proposals at June 18, 2026 AGM - The Globe and Mail

Immatics (IMTX) director Adam Leo Stone receives 48,000 stock options award - Stock Titan

Immatics (IMTX) awards director Alise Reicin 48,000 stock options - Stock Titan

Immatics (IMTX) director receives grant of 48,000 stock options at $9.09 - Stock Titan

Immatics (IMTX) director receives 48,000 stock options vesting in 2026 - Stock Titan

Immatics N.V. (IMTX) grants director options on 48,000 ordinary shares - Stock Titan

Immatics N.V. (IMTX) director awarded 48,000 stock options at $9.09 - Stock Titan

Immatics (IMTX) director Heather Mason receives 48,000 stock options at $9.09 strike - Stock Titan

48,000 Immatics (IMTX) options tied to board role granted - Stock Titan

Immatics (IMTX) director Mathias Hothum awarded 48,000 options at $9.09 strike - Stock Titan

Immatics N.V. (IMTX) 2026 AGM sees all voting items approved and strong turnout - Stock Titan

Immatics NV (IMTXW) Valuation: PE, PB & Fair Value Analysis - TradingKey

Immatics NV (IMTXW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Immatics NV (IMTXW) Institutional Confidence - TradingKey

Immatics NV (IMTXW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Immatics NV (IMTXW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Immatics NV (IMTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Immatics NV (IMTXW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Immatics NV (IMTXW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Immatics NV (IMTXW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

BNTX

$90.58

2.44%

INCY

$119.52

2.82%

ROIV

$33.91

1.77%

RPRX

$58.43

1.00%

ALNY

$205.52

0.02%

ONC

$316.01

1.88%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters